Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:52:23.372Z.
Calculation as of: 2026-10-06T16:52:23.372Z.
Quote observation: 2026-10-06T16:49:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 347a41eedf46a91d1f1a35dde2c997a021a555167078676fef94c90a8032fb0d
PE RATIO
N/A
Market Cap
$5.74B
PE Ratio
76.92
TTM Avg
136.52
3Y Avg
215.24
5Y Avg
141.48
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. Common Stock (MMED) | $5.53B | N/A | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.54B | N/A | 670.99 | 322.02 | 261.00 |
| CG Oncology Inc. (CGON)vs › | $5.69B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.32B | 33.46 | 29.46 | 43.55 | 46.11 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | 8.39 | 8.39 | 8.39 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 76.92 | 136.52 | 215.24 | 141.48 |
| Sotera Health Company (SHC)vs › | $5.27B | 32.31 | 70.23 | 85.34 | 112.40 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.19B | N/A | 17.47 | 59.21 | 59.21 |
| Cogent Biosciences, Inc. (COGT)vs › | $5.20B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.90B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
29.3
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$19.70
Forward EPS (Est.)
$0.67
Forward P/E
29.26
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
